Patients should be informed that LUMIGAN™ has been reported to cause increased growth and darkening of eyelashes and darkening of the skin around the eye in some patients. These changes may be permanent.
Some patients may slowly develop darkening of the iris, which may be permanent.
When only one eye is treated, patients should be informed of the potential for a cosmetic difference between the eyes in eyelash length, darkness or thickness, and/or color changes of the eyelid skin or iris.
Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, surrounding structures, fingers, or any other surface in order to avoid contamination of the solution by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Patients should also be advised that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, they should immediately seek their physicians advice concerning the continued use of the multidose container.
Patients should be advised that if they develop any ocular reactions, particularly conjunctivitis and eyelid reactions, they should immediately seek their physicians advice.
Contact lenses should be removed prior to instillation of LUMIGAN™ and may be reinserted 15 minutes following its administration. Patients should be advised that LUMIGAN™ contains benzalkonium chloride, which may be absorbed by soft contact lenses.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes between applications.
No Information Provided
LUMIGAN™ (bimatoprost ophthalmic solution) 0.03% is contraindicated in patients with hypersensitivity to bimatoprost or any other ingredient in this product.